|
2022 Conference Publication Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)Davis, Ian D., Martin, Andrew James, Zielinski, Robert Richard, Thomson, Alastair, Tan, Thean Hsiang, Sandhu, Shahneen, Reaume, M. Neil, Pook, David William, Parnis, Francis, North, Scott A., Marx, Gavin M., McCaffrey, John, McDermott, Raymond S., Lawrence, Nicola Jane, Horvath, Lisa, Frydenberg, Mark, Chowdhury, Simon, Chi, Kim N., Stockier, Martin R. and Sweeney, Christopher (2022). Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2022 Conference Publication TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603)Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2022). TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Virtual, 3-7 June 2022. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2022 Conference Publication DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiationNiazi, Tamim, McBride, Sean Matthew, Williams, Scott, Davis, Ian D., Stockler, Martin R., Martin, Andrew James, Bracken, Karen, Roncolato, Felicia, Horvath, Lisa, Sengupta, Shomik, Martin, Jarad, Lim, Tee, Hughes, Simon, McDermott, Raymond S., Catto, James W. F., Kelly, Paul J., Parulekar, Wendy R., Morgan, Scott Carlyle, Rendon, Ricardo A. and Sweeney, Christopher (2022). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.TPS284 |
|
2022 Journal Article ‘Pain-free TRUS B’: a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Hayne, Dickon, Grummet, Jeremy, Espinoza, David, McCombie, Steve P., Chalasani, Venu, Ford, Kate S., Frydenberg, Mark, Gilling, Peter, Gordon, Barbara, Hawks, Cynthia, Konstantatos, Alex, Martin, Andrew J., Nixon, Anthony, O’Brien, Colin, Patel, Manish I., Sengupta, Shomik, Shahbaz, Shekib, Subramaniam, Shalini, Williams, Scott, Woo, Henry H., Stockler, Martin R., Davis, Ian D. and Buchan, Nick (2022). ‘Pain-free TRUS B’: a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501). BJU International, 129 (5), 591-600. doi: 10.1111/bju.15552 |
|
2022 Journal Article Reply to L. Marandino et alStockler, Martin R., Martin, Andrew J., Dhillon, Haryana M., Davis, Ian D. and Sweeney, Christopher J. (2022). Reply to L. Marandino et al. Journal of Clinical Oncology, 30 (19) JCO.22.00497, 2176-2177. doi: 10.1200/JCO.22.00497 |
|
2022 Journal Article 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II TrialPathmanandavel, Sarennya, Crumbaker, Megan, Yam, Andrew O., Nguyen, Andrew, Rofe, Christopher, Hovey, Elizabeth, Gedye, Craig, Kwan, Edmond M., Hauser, Christine, Azad, Arun A., Eu, Peter, Martin, Andrew J., Joshua, Anthony M. and Emmett, Louise (2022). 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. Journal of Nuclear Medicine, 63 (4), 560-566. doi: 10.2967/jnumed.121.262552 |
|
2022 Journal Article Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUPStockler, Martin R., Martin, Andrew J., Davis, Ian D., Dhillon, Haryana M., Begbie, Stephen D., Chi, Kim N., Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E., Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin M., McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy R., Pook, David W., Reaume, M. Neil, Sandhu, Shahneen, Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Vera-Badillo, Francisco, Williams, Scott G., Winter, Diana G. ... Sweeney, Christopher J. (2022). Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP. Journal of Clinical Oncology, 40 (8), 837-846. doi: 10.1200/JCO.21.00941 |
|
2022 Conference Publication SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation scheduleHayne, Dickon, Swarbrick, Nicole, McCombie, Stephen, Moe, Andrew, Hawks, Cynthia, Viswambaram, Pravin, Conduit, Ciara, Liow, Elizabeth Chien Hern, Spalding, Lisa, Bothe, Jarrad, Ferguson, Tom, Martin, Andrew James, Davis, Ian D. and Redfern, Andrew David (2022). SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule. ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.483 |
|
2022 Conference Publication ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Martin, Andrew James, Zhang, Alison Yan, Yip, Sonia, Crumbaker, Megan, Rana, Nisha, Francis, Roslyn J., Hofman, Michael S., Joshua, Anthony M., Sandhu, Shahneen Kaur, Azad, Arun, Gedye, Craig, Weickhardt, Andrew James, Goh, Jeffrey C., Ng, Siobhan, Voskoboynik, Mark, McJannett, Margaret Mary, Stockler, Martin R. and Davis, Ian D. (2022). ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.TPS205 |
|
2022 Conference Publication PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of <SUP>177</SUP>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)Buteau, James Patrick, Martin, Andrew James, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen Kaur, Joshua, Anthony M., Zhang, Alison Yan, Francis, Roslyn J., Scott, Andrew Mark, Azad, Arun, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Davis, Ian D. and Hofman, Michael S. (2022). PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.010 |
|
2022 Conference Publication Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1<SUP>77</SUP>LuPSMA-617 and NOX66 (LuPIN)Pathmanandavel, Sarennya, Crumbaker, Megan, Yam, Andrew O., Nguyen, Andrew, Niman, Remy, Wilson, Peter, Sharma, Shikha, Ayers, Maria, Eu, Peter, Stockler, Martin R., Martin, Andrew James, Joshua, Anthony M. and Emmett, Louise (2022). Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 177LuPSMA-617 and NOX66 (LuPIN). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.166 |
|
2022 Conference Publication INTEGRATE IIb: A randomized phase III open label study of regorafenib plus nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC)Pavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin Marie, Martin, Andrew James, Jaworski, Anthony, Yip, Sonia, Oh, Do-Youn, Moehler, Markus H., Bekaii-Saab, Tanios S., Simes, John and Goldstein, David (2022). INTEGRATE IIb: A randomized phase III open label study of regorafenib plus nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC). ASCO Gastrointestinal Cancers Symposium, San Francisco Ca, Jan 20-22, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.4_suppl.TPS366 |
|
2022 Journal Article Effects of delayed versus immediate umbilical cord clamping in reducing death or major disability at 2 years corrected age among very preterm infants (APTS): a multicentre, randomised clinical trialRobledo, Kristy P, Tarnow-Mordi, William O, Rieger, Ingrid, Suresh, Preeti, Martin, Andrew, Yeung, Carbo, Ghadge, Alpana, Liley, Helen G, Osborn, David, Morris, Jonathan, Hague, Wendy, Kluckow, Martin, Lui, Kei, Soll, Roger, Cruz, Melinda, Keech, Anthony, Kirby, Adrienne, Simes, John, on behalf of the APTS Childhood Follow-up Study collaborators and Gardener, Glenn (2022). Effects of delayed versus immediate umbilical cord clamping in reducing death or major disability at 2 years corrected age among very preterm infants (APTS): a multicentre, randomised clinical trial. The Lancet Child and Adolescent Health, 6 (3), 150-157. doi: 10.1016/S2352-4642(21)00373-4 |
|
2021 Journal Article Quantifying the advantages of conducting a prospective meta-analysis (PMA): a case study of early childhood obesity preventionSeidler, A. L., Hunter, Kylie E., Espinoza, D., Mihrshahi, S., Askie, L. M., Askie, Lisa M., on behalf of the EPOCH Collaboration, Espinoza, David, Martin, Andrew, Daniels, Lynne A., Mihrshahi, Seema, Taylor, Rachael, Wen, Li Ming, Campbell, Karen, Hesketh, Kylie D., Rissel, Chris, Taylor, Barry, Magarey, Anthea, Seidler, Anna Lene and Baur, Louise A. (2021). Quantifying the advantages of conducting a prospective meta-analysis (PMA): a case study of early childhood obesity prevention. Trials, 22 (1) 78, 1-8. doi: 10.1186/s13063-020-04984-x |
|
2021 Journal Article Reacting to prognostic covariate imbalance in randomised controlled trialsCoskinas, Xanthi, Schou, I. Manjula, Simes, John and Martin, Andrew (2021). Reacting to prognostic covariate imbalance in randomised controlled trials. Contemporary Clinical Trials, 110 106544, 1-7. doi: 10.1016/j.cct.2021.106544 |
|
2021 Journal Article ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Joshua, Anthony M., Crumbaker, Megan, Martin, Andrew, Zhang, Alison Y., Rana, Nisha, Langford, Ailsa, Mitchell, Jenna, Yip, Sonia, Francis, Roslyn, Hofman, Michael S., Sandhu, Shahneen, Azad, Arun, Gedye, Craig, McJannett, Margaret, Stockler, Martin R. and Davis, Ian D. (2021). ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 128 (5), 642-651. doi: 10.1111/bju.15491 |
|
2021 Journal Article Do ethnic patients report longer lung cancer intervals than Anglo-Australian patients?: Findings from a prospective, observational cohort studyMazza, Danielle, Lin, Xiaoping, Walter, Fiona M., Young, Jane M., Barnes, David J., Mitchell, Paul L., Brijnath, Bianca, Martin, Andrew, O'Byrne, Kenneth J. and Emery, Jon D. (2021). Do ethnic patients report longer lung cancer intervals than Anglo-Australian patients?: Findings from a prospective, observational cohort study. European Journal of Cancer Care, 30 (6) e13492, 1-11. doi: 10.1111/ecc.13492 |
|
2021 Journal Article Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapySweeney, Christopher J., Martin, Andrew J., Stockler, Martin R., Begbie, Stephen, Chi, Kim N., Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E., Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin M., McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy, Pook, David W., Reaume, M. Neil, Sandhu, Shahneen K., Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Tu, Emily, Vera-Badillo, Francisco, Williams, Scott G., Yip, Sonia ... Davis, Ian D. (2021). Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 80 (3), 275-279. doi: 10.1016/j.eururo.2021.05.016 |
|
2021 Journal Article [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialHofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A. ... TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397 (10276), 797-804. doi: 10.1016/S0140-6736(21)00237-3 |
|
2021 Conference Publication P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs)Subramaniam, Shalini, Toner, Guy C., Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Jeffery, Mark, Mazhar, Danish, Huddart, Robert A., Walpole, Euan Thomas, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J., Wheater, Matthew James, Balagtas, Jay R., Troon, Simon, Birtle, Alison Jane, White, Jeff D. and Grimison, Peter S. (2021). P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs). ASCO Genitourinary Cancers Symposium (GU ASCO), Online, 11-13 February 2021. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2021.39.6_suppl.TPS390 |
